Quarterly Report • Nov 17, 2017
Quarterly Report
Open in ViewerOpens in native device viewer
Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the third quarter 2017. A presentation of the results by the Company's senior management team will take place today at 9.00 am CET in Oslo – details below.
"We are very pleased with the progress the company has made during Q3 2017. Our broad clinical development programme of Phase 2 trials with BGB324, our selective Axl inhibitor, in combination with standard therapies in multiple aggressive cancers is well underway and recruiting patients at leading hospitals in Europe and the US. These trials are on track to deliver important clinical milestones in 2H2018, demonstrating the significant potential of BGB324 to become a universal approach to cancer therapy by making tumour cells visible to the immune system and more susceptible to treatment with chemotherapy, targeted therapy and immuno-oncology drugs."
| Key Figures (NOK million) |
Q3 2017 |
Q3 2016 |
YTD2017 YTD2016 FY 2016 | ||
|---|---|---|---|---|---|
| Operating revenues | - | - | - | - | - |
| Operating expenses | 36.6 | 16.3 | 136.2 | 103.5 | 131.6 |
| Operating profit (loss) | (36.6) | (16.3) | (136.2) | (103.5) | (131.6) |
| Profit (loss) after tax | (35.4) | (15.4) | (134.6) | (101.9) | (129.8) |
| Basic and diluted earnings (loss) per share (NOK) |
(0.71) | (45.64) | (3.06) | (339.63) | (419.68) |
| Net cash flow in the period |
(41.1) | 82.1 | 237.3 | 113.2 | 87.8 |
| Cash position end of period |
399.2 | 187.2 | 399.2 | 187.2 | 161.8 |
A presentation by BerGenBio's senior management team will take place at 9.00 am CET at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished.
The results report and the presentation will be available at www.bergenbio.com in the section: Investors/Reports and presentations from 7:00 am CET the same day.
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of Axl kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers.
BerGenBio's lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated in the second half of 2018. It is the only selective Axl inhibitor in clinical development.
The Company sponsored clinical trials are:
The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc., Kenilworth, N.J., USA.
In addition, a number of investigator-sponsored trials are underway, including a trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining BGB324 with docetaxel in advanced NSCLC.
BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with BGB324. This will facilitate more efficient registration trials and support a precision medicine based commercialisation strategy.
The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-Axl monoclonal antibody.
For further information, please visit: www.bergenbio.com
KEYTRUDA®is a registered trademark of Merck Sharp &Dohme Corp., a subsidiary of Merck &Co., Inc., Kenilworth, NJ, USA, TARCEVA®is a registered trademark of OSI Pharmaceuticals, LLC., marketed byRoche-Genentech. TAFLINAR®is a registered trademark of Novartis International AGand MEKINIST®is a registered trademark of GSKplc.
Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 Tom Henrik Sundby Finance Director, BerGenBio ASA [email protected]
+47 477 54 415
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
+44 207 638 9571
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.